Premium
Evaluation and validation of the C ore L ower U rinary T ract S ymptom S core as an outcome assessment tool for the treatment of benign prostatic hyperplasia: Effects of the α1‐adrenoreceptor antagonist silodosin
Author(s) -
Ito Hiroki,
Sano Futoshi,
Ogawa Takehiko,
Yao Masahiro
Publication year - 2014
Publication title -
international journal of urology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.172
H-Index - 67
eISSN - 1442-2042
pISSN - 0919-8172
DOI - 10.1111/iju.12167
Subject(s) - silodosin , overactive bladder , lower urinary tract symptoms , medicine , international prostate symptom score , urology , urinary system , hyperplasia , prostate , pathology , alternative medicine , cancer
We investigated the C ore L ower U rinary T ract S ymptom S core as an outcome assessment tool for the treatment of lower urinary tract symptoms using silodosin. In addition, the ability of the C ore L ower U rinary T ract S ymptom S core to detect overactive bladder in male patients with lower urinary tract symptoms was examined. The present study included 241 males with benign prostatic hyperplasia treated at 31 medical facilities between J une 2009 and D ecember 2010. All patients were given silodosin, and the effects of silodosin intake were measured using four questionnaires: the C ore L ower U rinary T ract S ymptom S core, I nternational P rostate S ymptom S core, O veractive B ladder S ymptom S core and Q uality‐of‐ L ife index. The efficacy of silodosin for treating lower urinary tract symptoms was validated according to the total scores of all four questionnaires weighted equally ( P < 0.05). Spearman's ρ among the C ore L ower U rinary T ract S ymptom S core, I nternational P rostate S ymptom S core and O veractive B ladder S ymptom S core showed a mild‐high correlation. However, the correlation between the baseline values of the C ore L ower U rinary T ract S ymptom S core and Q uality‐of‐ L ife index was low in the groups with benign prostatic hyperplasia (ρ = 0.314) and benign prostatic hyperplasia/overactive bladder (ρ = 0.244). Our findings showed the C ore L ower U rinary T ract S ymptom S core, both its total score and each subscore, is able to show the efficacy of silodosin, similar to other questionnaires. The C ore L ower U rinary T ract S ymptom S core is also useful for identifying overactive bladder symptoms in patients with benign prostatic hyperplasia. As the C ore L ower U rinary T ract S ymptom S core does not correlate well with the Q uality‐of‐ L ife index, these two questionnaires might be better used in combination to assess treatment outcomes.